Transcatheter Technologies GmbH

NEW YORK, Oct. 20, 2023 /PRNewswire/ -- The Transcatheter Aortic Valve Replacement (TAVR) Market size is expected to increase by USD 2.34 billion, accelerating at a CAGR of 7.01% during the forecast period, according to Technavio market analysis. The report analyzes the market's competitive landscape and offers information on several market companies, including: 4C Medical Technologies Inc., Abbott Laboratories, Anteris Technologies Ltd., Artivion Inc., Biosensors International Group Ltd., Boston Scientific Corp., Colibri Heart Valve LLC, Edwards Lifesciences Corp., Genesis Medtech International Pvt. Ltd., HighLife SAS, JenaValve Technology Inc., LifeNet Health Inc., LivaNova Plc, Medinol Ltd., Medtronic Plc, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corp., Shockwave Medical Inc., Siemens AG, and Venus Medtech Hangzhou Inc. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. buy the report! Continue Reading Technavio has announced its latest market research report titled Global Transcatheter Aortic Valve Replacement Market 2023-2027 Transcatheter Aortic Valve Replacement (TAVR) Market 2023 – 2027: Company Profile: Abbott Laboratories: The company offers transcatheter aortic valve replacement, namely Navitor designed to treat aortic stenosis. To gain access to more company profiles available with Technavio, Read Free PDF Sample Report Transcatheter Aortic Valve Replacement (TAVR) Market 2023 – 2027: Geographical Analysis North America is expected to make a substantial 43% contribution to the global market's growth during the forecast period. Key factors significantly fueling the growth of the transcatheter aortic valve replacement (TAVR) market in North America include the elevated prevalence of heart-related conditions like heart valve diseases, stenosis, and atresia, the increasing adoption of suture-less valves, tissue valves, and minimally invasive procedures, and the rapid expansion of the older adult population. Transcatheter Aortic Valve Replacement (TAVR) Market 2023 – 2027: Segmentation Analysis The market is segmented by End-user (Hospitals, Ambulatory surgical centers, and Others), Type (Balloon-expanding valve and Self expanding valve), and Geography (North America, Europe, Asia, and Rest of World (ROW)). During the forecast period, substantial growth is expected in the hospital segment. This particular segment serves as the principal end-user for minimally invasive cardiac procedures, making a significant contribution to the global transcatheter aortic valve replacement (TAVR) market. Within this segment, a variety of healthcare facilities are included, ranging from prominent academic medical centers to community hospitals. These facilities have specialized infrastructure and a highly skilled medical workforce capable of performing TAVR procedures safely and effectively. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a Free PDF Sample Report Transcatheter Aortic Valve Replacement (TAVR) Market 2023 – 2027: Driver & Trend: Driver Growing global aging population, with 10% over 65 years in 2022 and a projected increase to 16% by 2050. Increasing prevalence of aortic valve disease, particularly aortic stenosis, among older individuals. Extended life expectancy due to improved healthcare and living conditions. Elevated demand for transcatheter aortic valve replacement (TAVR) procedures because of these demographic shifts, positively impacting market growth during the forecast period. Trend - A key factor shaping the transcatheter aortic valve replacement market growth is the growing expansion of indications for TAVR procedures. Identify key trends, drivers, and challenges in the market. Download the free sample report now to gain access to this information Related Reports : Transcatheter Pulmonary Valve Market : The transcatheter pulmonary valve market share is expected to increase by USD 51.74 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 6.1%. Angio Suites Market : The angio suites market is estimated to grow at a CAGR of 5.65% between 2022 and 2027. The size of the market is forecasted to increase by USD 819.65 million. What are the key data covered in this transcatheter aortic valve replacement market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the transcatheter aortic valve replacement market between 2022 and 2027. Precise estimation of the transcatheter aortic valve replacement market size and its contribution to the market in focus on the parent market Accurate predictions about upcoming trends and changes in consumer behavior A thorough analysis of the market's competitive landscape and detailed information about vendors Comprehensive analysis of factors that will challenge the growth of transcatheter aortic valve replacement market vendors. TOC: Executive Summary Market Landscape Market Sizing Historic Market Sizes Five Forces Analysis Market Segmentation by End-User Market Segmentation by Type Market Segmentation by Geography Customer Landscape Geographic Landscape Drivers, Challenges, & Trends Company Landscape Company Analysis Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

The implantation of Peijia's Highlife TSMVR system was performed by Professor Mao Chen and his team of West China Medical Center of Sichuan University as part of a research clinical trial On December 22, 2021, the first clinical case using HighLife transseptal mitral valve replacement (“TSMVR”) technology was successfully carried out in Asia. The implantation of Peijia’s Highlife TSMVR system was performed by Professor Mao Chen and his team of West China Medical Center of Sichuan University as part of a research clinical trial. The patient is a 74-year-old female who was recently hospitalized for recurrent acute left heart failure, as well as persistent atrial fibrillation, hypertension, diabetes and other medical illnesses. The operation went smoothly with optimal positioning and good post-procedural outcome. The mitral valve regurgitation was eliminated immediately after the procedure with no LVOT obstruction. The patient has been recovering well, and was transferred from the intensive care unit (ICU) to a general ward the next day with normal cardiac function. She was discharged from the hospital on December 30, 2021. This successful procedure laid a solid foundation for future clinical cases of Peijia’s HighLife TSMVR system in China. “The unique ‘Valve-in-Ring’ design makes it suitable for wide range of mitral valve anatomy.” said Professor Mao Chen. “Most patients won’t need atrial septal defect closure after transseptal puncture with 30F delivery catheter, and the probability of vascular complications is relatively low. The procedure is performed under standard DSA in conjunction with echocardiogram, which will promote the adoption of this technology. I hope that this technology can be applied to more clinical uses in the near future to benefit patients with mitral regurgitation.” HighLife technology offers unique features for treating mitral valve insufficiency. Transcatheter Mitral Valve Replacement (“TMVR”) has been trending in the field of interventional therapy of structural heart disease. Early exploratory studies have proved the safety and efficacy of this technology. TMVR is suitable for wider anatomical characteristics of mitral regurgitation (“MR”). It can reduce or even completely eliminate regurgitation and the patient outcomes are usually sustainable. Furthermore, TMVR is less invasive and can be performed on elderly or high-risk patients when compared to surgical replacement. However, the field of Mitral Valve Replacement still faces many technical difficulties, including access to the target site, anchoring and the risk of paravalvular leakage (“PVL”) and LVOT obstruction. Most existing approaches are either transapical or anchoring using radial force. Transapical TMVR can lead to the weakening of the left ventricular wall muscle or even a default in left ventricular beating due to surgical incision. TMVR anchoring with radial force can result in a large valve size and difficulty in delivery, which can potentially lead to left ventricular reverse remodeling. The HighLife TSMVR system employs a unique “Valve-in-Ring” concept which can better cope with these challenges. This system separates the valve from its anchoring ring and delivers the two components through the femoral vein and femoral artery respectively. It is a simple three-step procedure. First, a guide wire loop is placed around the patient’s native valve leaflets and chordae. Secondly, the anchoring ring is implanted. Finally, the self-expanding bovine pericardial valve is released through transseptal access. The delivered valve is anchored by interacting and then reaching an equilibrium position with the previously positioned ring. This allows the valve to remain in a stable position without damaging the original tissue. The procedure is relatively simple as the system is self-centering and self-aligning. The system’s design helps to mitigate the risk of paravalvular leakage and effectively reduces catheter size. The procedure can be successfully completed using teleproctoring support. Peijia Medical demonstrated its capability in international collaboration and technical expertise In December 2020, Peijia Medical entered into a license agreement with HighLife SAS, a France based medical device company, pursuant to which HighLife SAS has granted Peijia Medical an exclusive license to develop, manufacture and commercialize certain proprietary TMVR products in the Greater China region. This technology transfer was completed in the third quarter of 2021. Local manufacturing with high quality standards in China has been established: the HighLife device produced by Peijia Medical passed all performance tests demonstrating substantially equivalent to HighLife SAS. From the start of the technology transfer to the first implantation in research clinical trial in China, Peijia Medical took less than one year to complete the process which demonstrated its capability in international collaboration and technical expertise. To expediate the use of this world-leading technology for the benefits of MR patients in China, Peijia Medical’s consultants, Professor Nicolo Piazza and Professor Jean Buithieu from McGill University Medical Center in Canada, and the technical experts from HighLife SAS worked closely together with Peijia Medical to prepare for this clinical trial. Several training sessions involving device related and clinical practice were conducted and Cardiologists in China also actively participated in the process to ensure successful implantation. Dr. Nicolo Piazza thought highly of this collaboration and successful implantation. “I am very glad and honored to support Professor Mao Chen and his team remotely to carry out the HighLife TSMVR procedure and share my technical experience. I was also amazed by the superb technique and tacit cooperation of Professor Mao Chen and the team. I am very happy for the successful implant of the first TSMVR system in Asia. I believed HighLife TSMVR system can benefit more patients in the future, and I look forward to more vigorous development in the field of mitral valve interventional therapy.” Adherence to its vision of “Devotion to the Heart, Reverence for Life”, Peijia Medical strives to improve patients’ quality of life through technological exploration and innovative persistence. “We have seen more studies on how TMVR technology targets the challenges stemming from the complex anatomy of the mitral valve and the severity of the disease. These continuous efforts signal the importance of TMVR therapy,” said Dr. Michael Zhang Yi, Chairman and CEO of Peijia Medical. “Even though transseptal approach is a preferred route and excels in many ways, most existing TMVR technologies still employ a transapical approach. HighLife SAS is a global leader in the TSMVR technology, with promising clinical trial outcomes published in TCT 2021 and PCR London Valves 2021. Thanks to Professor Mao Chen and Professor Nicolo Piazza for their collaboration on the first implantation of Peijia’s HighLife System, the successful implantation has further strengthened our confidence in treating mitral valve diseases with truly minimally invasive interventional technology. Peijia Medical will continue our dedication towards innovation, in the hopes that more Chinese patients who suffer from mitral valve disease can benefit from such technological advancements.” Peijia’s HighLife TSMVR system represents the state-of-the-art mitral valve interventional therapy, which will greatly improve the quality of life of Chinese patients with severe MR. Peijia Medical’s belief “to place patients’ lives and safety at the forefront through advancing the development of minimum invasive medical therapies at home and abroad” has never changed.

Covina, CA, June 10, 2021 (GLOBE NEWSWIRE) -- The Transcatheter Mitral valve replacement market accounted for US$ 0.92 billion in 2020 and is estimated to be US$ 14.5 billion by 2030 and is anticipated to register a CAGR of 31.4%.Mitral valve dysfunction happens when the valve does not function properly, causing irregular blood flow. This irregular blood flow causes two diseases: mitral valve prolapse and regurgitation. The mitral valve is located between the left atrium and the left ventricle. For patients who are unable or unwilling to undergo surgery, transcatheter mitral valve replacement (TMVR) has emerged as an alternative treatment option. Transcatheter mitral valve replacement provides excellent hemodynamic efficiency with a low rate of residual mitral regurgitation and low transvalvular gradients. Request a Free Sample Copy of this Business Intelligence Report @  The report " Transcatheter Mitral valve Replacement Market, By Product (mechanical valve and Bioprosthetic tissue valve), By Diagnostic test (lateral flow assay, PCR assay, latex Agglutination tests),By End-user (hospital, clinics and others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030” Key Highlights: Ask for a Discount on the Current Pricing @  Analyst View: Because of increasing incidences of mitral valve diseases, new pipeline devices, and an ageing population with heart disorders, demand for Transcatheter Mitral Valve Implantation (repair and replacement) is projected to grow at a healthy pace during the forecast era. Due to an increase in the geriatric population and an increase in mitral valve disorders, Technological advancements and the introduction of new mitral valves are two other factors that lead to market development. In terms of safety and efficacy, these interventions are proving to be beneficial for patients who are at risk of developing mitral valve disease. Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Transcatheter Mitral valve Replacement Market, By Product (mechanical valve and Bioprosthetic tissue valve), By Diagnostic test (lateral flow assay, PCR assay, latex Agglutination tests),By End-user (hospital, clinics and others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030” To know the upcoming trends and insights prevalent in this market, click the link below: Key Market Insights from the report: The Transcatheter Mitral valve replacement market accounted for US$ 0.92  billion in 2020 and is estimated to be US$ 14.5 billion by 2030 and is anticipated to register a CAGR of 31.4%. The Transcatheter Mitral valve replacement Market is segmented based on the product, application, end-use and region. Competitive Landscape: The key players operating in the Transcatheter Mitral valve replacement market includes Abbott Laboratories, Biotronik Pvt Ltd, Colibri Heart Valve, LLC, Edward Lifesciences, HLT Medical, LivaNova Plc, Medtronic Plc, Neovasc Inc., NeoChord, Venus Medtech, Transcatheter Technologies GmbH, MValve Technologies and Mardil Medical. The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report. About Prophecy Market Insights Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business. Some Important Points Answered in this Market Report Are Given Below: Key Topics Covered Browse Related Reports: